[Skip to Navigation]
Sign In
Comment & Response
March 2018

Brain Metastases in Lung Cancer With Targetable Mutations: Should We Allow Targeted Treatment in Prognostic Indices?

Author Affiliations
  • 1Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia
JAMA Oncol. 2018;4(3):421-422. doi:10.1001/jamaoncol.2016.7022

To the Editor In a recent article,1 Sperduto and colleagues provided an update to their seminal work developing the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with brain metastases.2 In addition to the initial factors that formed the DS-GPA for lung cancer—patient age, Karnofsky Performance Status, extracranial metastases, and number of brain metastases—presence of EGFR mutation and ALK rearrangement were found to further characterize a favorable cohort with a median overall survival of almost 4 years after incorporation of molecular markers into the prognostication scheme. These findings contrast with the 14.8-month median survival seen in the most favorable subset from the initial publication.

Add or change institution